In context
Trofinetide is the active ingredient in Daybue and Daybue Stix. Their US indication is Rett syndrome in adults and children aged two years and older. [1]
At a glance
- Type
- Peptide analogue medicine
- Regulatory context
- United States: Daybue and Daybue Stix have a Rett-syndrome indication for patients aged two years and older.
- Evidence
- Evidence and regulatory labelling concern Rett syndrome; they do not establish a general cognitive-enhancement use.
Clinical context
Rett syndrome is the condition named in the US product label. Trofinetide should not be treated as interchangeable with investigational analogues or older development programmes. [1]
Reading the evidence
A disease-specific indication does not demonstrate benefit for otherwise healthy people. Formulation, age and clinical context remain essential to interpreting a study. [1]
Development terminology
A predecessor programme is not a distinct authorised medicine. This index maps that phrase to the trofinetide guide without transferring its label to other research candidates. [1]
Safety and clinical context
Consult the current product-specific prescribing information. A general peptide category cannot describe an individual patient's risk or suitability.
Evidence and authorisation depend on the product, formulation, indication and country. US labelling does not establish Thai authorisation. This guide is educational and is not a dosing or self-treatment protocol.
Primary sources
Read the underlying source and its limitations. A study citation does not by itself establish efficacy or approval.
- Daybue — US prescribing information dailymed.nlm.nih.gov